Sponsored by
GammaTile is an FDA-cleared treatment option for both newly diagnosed and recurrent malignant brain tumors, such as Glioblastomas and metastatic tumors. This innovative therapy involves the surgical insertion of radiation-emitting wafers at the time of surgery, precisely targeting the affected area. Unlike external beam radiation, GammaTile begins its therapeutic effects immediately, potentially eliminating the need for additional radiation treatments and significantly benefiting patients in terms of convenience and time savings. This groundbreaking treatment has been readily accessible for three years and is currently available in over 80 hospitals across the United States.